Switch theme
Sign up to access all valuation multiples
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
1992
2.7K+
LTM Revenue n/a
LTM EBITDA n/a
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Star Lake Bioscience has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Star Lake Bioscience achieved revenue of $2.4B and an EBITDA of $260M.
Star Lake Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Star Lake Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.4B | XXX | XXX | XXX |
| Gross Profit | $42.2M | $425M | XXX | XXX | XXX |
| Gross Margin | 2% | 18% | XXX | XXX | XXX |
| EBITDA | $365M | $260M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 11% | XXX | XXX | XXX |
| Net Profit | $14.7M | $83.8M | XXX | XXX | XXX |
| Net Margin | 1% | 4% | XXX | XXX | XXX |
| Net Debt | $10.7M | $340M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Star Lake Bioscience's stock price is CNY 7 (or $1).
Star Lake Bioscience has current market cap of CNY 11.1B (or $1.5B), and EV of CNY 13.0B (or $1.8B).
See Star Lake Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.5B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Star Lake Bioscience has market cap of $1.5B and EV of $1.8B.
Star Lake Bioscience's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Star Lake Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Star Lake Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.9x | XXX | XXX | XXX |
| P/E | 16.4x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | 7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStar Lake Bioscience's NTM/LTM revenue growth is n/a
Star Lake Bioscience's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Star Lake Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Star Lake Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Star Lake Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 7% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Star Lake Bioscience acquired XXX companies to date.
Last acquisition by Star Lake Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Star Lake Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Star Lake Bioscience founded? | Star Lake Bioscience was founded in 1992. |
| Where is Star Lake Bioscience headquartered? | Star Lake Bioscience is headquartered in China. |
| How many employees does Star Lake Bioscience have? | As of today, Star Lake Bioscience has 2.7K+ employees. |
| Is Star Lake Bioscience publicy listed? | Yes, Star Lake Bioscience is a public company listed on SHG. |
| What is the stock symbol of Star Lake Bioscience? | Star Lake Bioscience trades under 600866 ticker. |
| When did Star Lake Bioscience go public? | Star Lake Bioscience went public in 1994. |
| Who are competitors of Star Lake Bioscience? | Similar companies to Star Lake Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Star Lake Bioscience? | Star Lake Bioscience's current market cap is $1.5B |
| What is the current revenue growth of Star Lake Bioscience? | Star Lake Bioscience revenue growth between 2023 and 2024 was -1%. |
| Is Star Lake Bioscience profitable? | Yes, Star Lake Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
